CTOs on the Move

Vermont Nurse Alliance of Vermont and New Hampsh

www.vnhcare.org

 
Visiting Nurse and Hospice for Vermont and New Hampshire (VNH) is a non‐profit organization that has provided home health and hospice care services in Vermont and New Hampshire since 1907. The agency is dedicated to delivering outstanding home- and community-based health and hospice services that enrich the lives of the people they serve. VNH makes home visits to people of all ages and all stages of life – regardless of ability to pay – and also provides communities with education and wellness programs. Currently, VNH serves more than 150 towns in Vermont and New Hampshire and covers 4,000 square miles. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vnhcare.org
  • 88 Prospect Street
    White River Junction, VT USA 05001
  • Phone: 888.300.8853

Executives

Name Title Contact Details

Similar Companies

Steute Meditech

Steute Meditech is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedTrak Pharmacy Svcs

MedTrak Pharmacy Svcs is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Airport Health Club

Airport Health Club is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Airport Health Club is based in Santa Rosa, CA. You can find more information on Airport Health Club at www.airportclub.com

Inland Imaging Svc

Inland Imaging Svc is a Grand Terrace, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.